>Innovation is key to tackling AMR says Professor Dame Sally Davies, Chief Medical Officer for England 

'The world is fast approaching a crossroads on antimicrobial resistance (AMR). If we don’t all take sufficient action now, as nations, organisations, and individuals, we risk losing one of the greatest achievements of modern medicine — one that we all take for granted.

Innovation is key to tackling AMR and there are fantastic examples of this happening in communities all around the world, some of which will be showcased at the Call to Action event. We must find a way to unite, to learn from one another and scale-up these ideas to address the global threat of AMR. I call upon leaders at the second Call to Action to build upon the momentum generated and continue working towards a unified, global response.'

Dame Sally Davies, UK CMO speaking at Accra, Ghana, 2nd Call for Action, 19 November 2018.

"Nature makes penicillin, I just found it" - Sir Alexander Fleming

Nature can provide great templates and models for the development of new drugs against these hard-to-kill bacteria,” said Monique van Hoek, a professor with Mason’s National Center for Biodefense and Infectious Diseases, who along with chemistry professor Barney Bishop founded Antimicrobial Discovery Research in the College of Science, George Mason University, Virginia.

>World Economic Forum: Scientists are looking to insects for the next blockbuster medicine

>Microbes hitched to insects provide a rich source of new antibiotics

February 1, 2019 By Eric Hamilton For news media Source: University of Wisconsin-Madison Summary: The largest and most thorough study to assess insect-associated microbes for antibiotic activity to date has found that insect-borne microbes often outperformed soil bacteria in stopping some of the most common and dangerous antibiotic-resistant pathogens.

An exhaustive search of microbes from more than 1,400 insects collected from diverse environments across North and South America found that the same class of bacteria that gave us many of our antibiotics, known as Streptomyces, makes a home not just in the soil but all over, including on insects. 50,000 trials tested each microbe's ability to inhibit the growth of 24 different bacteria and fungi, many of which, like methicillin-resistant Staphylococcus aureus, better known as MRSA, pose serious threats to human health. A greater proportion of insect-associated microbes were able to inhibit the growth of these bacterial or fungal targets than were microbes isolated from soil or plants.

A new antibiotic from a Brazilian fungus-farming ant, was discovered. Named Cyphomycin, it was found effective in lab tests against fungi resistant to most other antibiotics and combatted fungal infections without causing toxic side effects in a mouse model. The researchers have submitted a patent based on cyphomycin because of its effectiveness in these early tests, setting up the team to begin to do the significant additional work required before cyphomycin could be developed into a new drug used in the clinic. The work was published Jan. 31 in the journal Nature Communications. Download report pdf.

>Cicada Wings: Novel antimicrobial surfaces to combat AMR infections in medical implants and devices
 July 2018. Lead Research Organisation: University of Bristol  Department Name: Oral and Dental Science

This innovative project explored a unique physical means to combat biomaterial-associated bacterial infections, utilising novel surfaces that kill bacteria with nanospikes, that resemble the nanotextured surfaces found on cicada wings in nature and have already been shown to be effective at killing certain bacteria by us. 

Read More

>US Researchers discover a strong anti-bacterial in blood molecule of Komodo dragon.

08 November 2017.
A research team at George Mason University, Virginia’s largest public research university,  has identified a molecule with antibacterial properties in the blood of the Komodo dragon. The federal government’s Defense Threat Reduction Agency (DTRA) funded the research with a $7.57 million contract for the George Mason team to analyze peptides used by such “extreme animals” as Komodo dragons and American alligators to defend against infection, potentially leading to new drugs and strategies to fight infection and protect the warfighter from bacterial bioweapons. These evolutionarily ancient reptiles could be a new source for antibiotics—they dine on carrion and live in bacteria-rich environments but rarely fall ill.

>Healed by a Crocodile: the Search for New Antibiotics: Monique van Hoek at TEDx George Mason University
Dr. Monique van Hoek is a scientist in search of interesting and useful problems. Using her training in biochemistry (UVIC, BSc, 1990) and microbiology (UVA, PhD, 1997), combined with her experience in industry, she is currently seeking new approaches to antibiotics in the face of the impending crisis of antibiotic resistance. She has spent the last several years focused on bacterial biofilms, the "resistance cloaks" produced by many bacteria, and has developed several compounds that can disrupt these biofilms. This talk describes the current status of antibiotics, and how we can look to our reptile cousins for solutions to the rising problem. 

>Armor-like shark skin may offer defense from superbugs  

Published on 27 Mar 2015.
Do sharks offer a key to fighting deadly bacteria? The White House unveiled a new campaign Friday to contain drug-resistant bacteria known as “superbugs,” and one of the unlikely resources that researchers are turning to is shark skin. Hari Sreenivasan reports.

>BIOTECH calls for fast track process to combat antimicrobial resistance threat.
Matoke Holdings has called on Government to provide a fast-track process to get new drugs to market to combat the global threat of antimicrobial resistance (AMR), at a meeting of key parliamentarians. Representing small and medium-sized companies, Ian Staples, Chief Executive of British biotech Matoke Holdings, called on the House of Lords Science and Technology Committee to help ensure that life-saving drugs can get through the regulatory process faster. The Committee was taking evidence as part of its ‘Life Sciences and the Industrial Strategy’ inquiry.

Commenting on Sir John Bell’s recent Life Sciences Strategy – a landmark deal for the life sciences sector – Staples said the plan must go further to provide end-to-end support through the regulatory process, from the laboratory to the NHS, for small biotech firms. He added that the costs and timescales involved in completing the regulatory process represent a significant barrier to innovation.

Staples outlined to the Committee the challenges faced by SMEs in bringing much needed innovative technology through the regulatory process to the market to tackle AMR. The regulatory challenge contributes to a significant gap between the antimicrobial pipeline and health needs: there are around only 17 SMEs currently working on developing new drugs to combat antimicrobial resistance in the UK and there have been no new antibiotics for the last 30 years.


“Antimicrobial resistance is a global crisis, and more must be done to get new antibiotics quickly and effectively through the regulatory process to tackle this.

The Government must take action to ensure clear pathways for small innovative British businesses to bring life-saving treatments out of the laboratory and into the NHS.   The costs and timescales involved in completing the regulatory process represent a significant barrier to innovation.” 

Ian Staples, Chief Executive of Matoke Holdings.

>UK-CHINA Collaborate to support development of innovation projects.
The Department of Health – working in collaboration with Innovate UK – is to invest up to £10 million of Official Development Assistance (ODA) funding in bilateral R&D projects between the UK and China which address the growing threat of antimicrobial resistance.

This is for innovation projects to support the development and, where appropriate, clinical evaluation, of new products or services. These products or services must be of value in addressing the threat from antimicrobial resistance (AMR).

The Chinese Ministry of Science and Technology (MoST) will invest up to 60 million RMB to fund the Chinese partners.

A global innovation Foundation seeking and backing new ideas to tackle the big challenges of our time from the pressures of an ageing population to stretched public services and a fast changing jobs market. By 2021 Nesta will have…Enabled the development of a rapid, accurate, safe and affordable point-of-care diagnostic test that can reduce inappropriate antibiotic use globally.

>INNOVATE UK: Antimicrobial resistance (AMR) - Time to behave like a real Ostrich

Posted on 2nd May 2018 by:Phil Packer,  Blog on the work of Innovate UK. Contributors are Innovate UK staff and our wider family, partners and experts from the world of innovation.

Of course, it is a myth that ostriches bury their heads in the ground at the sign of danger. Rather they stand and face it head on.

We need to act now

It is estimated that over 700,000 people die each year across the world from drug resistant infections. By 2050 this will be 10,000,000.  Without effective antimicrobials for prevention and treatment of infections, medical procedures such as organ transplantation, cancer chemotherapy, diabetes management and major surgery become very high risk. In the UK, sepsis (caused by bacterial infection) causes over 44,000 deaths each year; more than from lung cancer (35,000) and bowel cancer (16,000). Many of these sepsis deaths are due to untreatable antibiotic resistant infections. If there were no new antibiotics, then any infection becomes untreatable.

Innovate UK works with people, companies and partner organisations to find and drive the science and technology innovations that will grow the UK economy. They drive growth by working with companies to de-risk, enable and support innovation.

A One Health approach is needed to fight antibiotic resistance – everyone has a role to play to improve antibiotic prescribing and use. Join the global fightback against AMR